Clearmind Medicine Inc., a clinical-stage biotech company, has announced the filing of a U.S. patent application for a novel psychedelic-based treatment aimed at eating disorders. The treatment involves the use of 3-methylmethcathinone (3-MMC) either alone or in combination with Palmitoylethanolamide (PEA). The company, listed on Nasdaq and the Frankfurt Stock Exchange, is positioning itself at the forefront of the weight loss pharmaceutical sector, which is projected to grow significantly due to rising obesity rates worldwide. Clearmind's patent application is part of its broader strategy to develop and commercialize psychedelic-derived therapeutics for major health issues, including alcohol use disorder. The company's intellectual property portfolio currently includes sixteen patent families. The announcement was made on April 10, 2024, and the information was also incorporated by reference into Clearmind's Registration Statements on Form F-3 with the SEC.

Clearmind Medicine Inc., a clinical-stage biotech company, has announced the filing of a U.S. patent application for a novel psychedelic-based treatment aimed at eating disorders. The treatment involves the use of 3-methylmethcathinone (3-MMC) either alone or in combination with Palmitoylethanolamide (PEA). The company, listed on Nasdaq and the Frankfurt Stock Exchange, is positioning itself at the forefront of the weight loss pharmaceutical sector, which is projected to grow significantly due to rising obesity rates worldwide. Clearmind's patent application is part of its broader strategy to develop and commercialize psychedelic-derived therapeutics for major health issues, including alcohol use disorder. The company's intellectual property portfolio currently includes sixteen patent families. The announcement was made on April 10, 2024, and the information was also incorporated by reference into Clearmind's Registration Statements on Form F-3 with the SEC.